Blue Trust Inc. Sells 40,984 Shares of Pfizer Inc. (NYSE:PFE)

Blue Trust Inc. trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 47.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,321 shares of the biopharmaceutical company’s stock after selling 40,984 shares during the quarter. Blue Trust Inc.’s holdings in Pfizer were worth $1,258,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. GoalVest Advisory LLC raised its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in Pfizer during the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its holdings in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter worth about $36,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $35.54.

Pfizer Stock Up 1.3 %

NYSE PFE traded up $0.35 during trading on Friday, hitting $28.05. The stock had a trading volume of 17,268,657 shares, compared to its average volume of 27,585,572. The company has a market capitalization of $158.95 billion, a PE ratio of -467.42, a P/E/G ratio of 1.09 and a beta of 0.69. The company’s 50-day moving average price is $28.09 and its two-hundred day moving average price is $27.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.99%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.